Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Women in R&D and manufacturing functions by Year
Women in R&D and manufacturing functions (%) (%)
Moderna Women in R&D and manufacturing functions: 50.0% in FY2025, up 8.0 pts from a year earlier.
Latest, FY2025
50.0%
Period ended Dec 31, 2025
Change on a year earlier
+8.0 pts
42.0% in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
“Women in R&D and 50% 42% 50%”
Source: 2025 Impacting Human Health Report ↗
Reported in Moderna Corporate Responsibility / Impacting Human Health Reports.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Women in R&D and manufacturing functions (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50.0% | +8.0 pts | 2025 Impacting Human Health Report ↗ |
| FY2024 | Dec 31, 2024 | 42.0% | -8.0 pts | 2025 Impacting Human Health Report ↗ |
| FY2023 | Dec 31, 2023 | 50.0% | 0.0 pts | 2025 Impacting Human Health Report ↗ |
| FY2022 | Dec 31, 2022 | 50.0% | – | 2024 Impacting Human Health Report ↗ |
Cite this data
StockData. (2026). Moderna Women in R&D and manufacturing functions (%), annual FY2022–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/hc-women-rd-mfg-pct
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.